{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:55:29Z","timestamp":1773971729057,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Based on findings from the GEMSTONE-303 trial, the sugemalimab plus capecitabine and oxaliplatin regimen showed superior clinical efficacy compared to chemotherapy alone in advanced gastric cancer patients. This economic evaluation study assesses the cost-effectiveness of sugemalimab combination therapy within China\u2019s healthcare system framework.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A partitioned survival model was constructed based on data from the GEMSTONE-303 study, with a cycle length of 3\u202fweeks. The model simulated patients\u2019 direct medical costs and quality-adjusted life years (QALYs) over a 10-year period. The incremental cost-effectiveness ratio (ICER) was used as the evaluation metric, comparing the ICER against the willingness-to-pay (WTP) threshold (3 times China\u2019s per capita GDP in 2024, 287,391 CNY\/QALY). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base-case analysis showed that the sugemalimab regimen provided greater health benefits compared to the placebo group (1.36 QALYs vs. 1.24 QALYs) but incurred significantly higher costs (271,041.24 CNY vs. 44,174.69 CNY), yielding an ICER of 1,890,554.58 CNY\/QALY. One-way sensitivity analysis indicated that the utility values for the progressive disease (PD) state, progression-free survival (PFS) state, and the cost of sugemalimab had the most substantial impact on the ICER. Probabilistic sensitivity analysis demonstrated stable results, with a 0% probability that the sugemalimab combination regimen was cost-effective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Under the current economic conditions in China, sugemalimab combined with chemotherapy as a first-line treatment for advanced gastric cancer is not cost-effective.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1620663","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:37:49Z","timestamp":1753940269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Lian","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LongXun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShaoQing","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.7507\/1007-9424.202406046","article-title":"Interpretation of \"global cancer statistics 2022\": comparison between China and the world","volume":"31","author":"Yao","year":"2024","journal-title":"Chin J Bases Clin Gen Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3969\/j.issn.1000-8179.2017.01.88","article-title":"Current epidemiological status of gastric cancer in China","volume":"44","author":"Zuo","year":"2017","journal-title":"Chin J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1158\/1538-7445.AM2020-3260","article-title":"Abstract 3260: the preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation","volume":"80","author":"Zhang","year":"2020","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-line Sugemalimab plus chemotherapy for advanced gastric Cancer: the GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"key":"ref12","first-page":"167","article-title":"Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume-title":"J Natl Compr Canc Netw.","author":"Ajani","year":"2022"},{"key":"ref13","year":"2022"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","article-title":"VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) cancer: phase III KEYNOTE-859 study","volume":"34","author":"Rha","year":"2023","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"17588359231171038","DOI":"10.1177\/17588359231171038","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis","volume":"15","author":"Cao","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737167.2024.2378986","article-title":"Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis","volume":"24","author":"Zheng","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","article-title":"Ramucirumab for treating advanced gastric Cancer or gastro-Oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE single technology appraisal","volume":"35","author":"B\u00fcy\u00fckkaramikli","year":"2017","journal-title":"PharmacoEconomics"},{"key":"ref18","first-page":"27","volume-title":"China guidelines for pharmacoeconomic evaluation 2020","author":"Liu","year":"2020"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12874-022-01567-z","article-title":"KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves","volume":"22","author":"Zhao","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"924126","DOI":"10.3389\/fphar.2022.924126","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref21","year":"2020"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"818579","DOI":"10.3389\/fphar.2022.818579","article-title":"Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation in China","volume":"13","author":"Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17562848231207200","DOI":"10.1177\/17562848231207200","article-title":"Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer: a cost-effectiveness analysis","volume":"16","author":"Zhu","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1411571","DOI":"10.3389\/fphar.2024.1411571","article-title":"Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China","volume":"15","author":"Xiang","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1620663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:37:52Z","timestamp":1753940272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1620663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":24,"alternative-id":["10.3389\/fpubh.2025.1620663"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1620663","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"1620663"}}